Sanofi ADR (NASDAQ: SNY) has a higher price-to-earnings ratio of 31.76x compared to its average ratio, The 36-month beta value for SNY is at 0.56. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SNY is 2.51B, and currently, shorts hold a 0.45% of that float. The average trading volume for SNY on September 11, 2024 was 2.24M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SNY) stock’s latest price update
Sanofi ADR (NASDAQ: SNY) has seen a decline in its stock price by -0.89 in relation to its previous close of 58.13. However, the company has experienced a -1.56% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-11 that Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines Data will support regulatory resubmission in the US by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines.
SNY’s Market Performance
Sanofi ADR (SNY) has experienced a -1.56% fall in stock performance for the past week, with a 10.42% rise in the past month, and a 18.77% rise in the past quarter. The volatility ratio for the week is 1.30%, and the volatility levels for the past 30 days are at 1.04% for SNY. The simple moving average for the past 20 days is 2.78% for SNY’s stock, with a 16.27% simple moving average for the past 200 days.
Analysts’ Opinion of SNY
Many brokerage firms have already submitted their reports for SNY stocks, with Argus repeating the rating for SNY by listing it as a “Buy.” The predicted price for SNY in the upcoming period, according to Argus is $60 based on the research report published on July 26, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see SNY reach a price target of $55. The rating they have provided for SNY stocks is “Equal-Weight” according to the report published on January 23rd, 2024.
SNY Trading at 8.61% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.30% of loss for the given period.
Volatility was left at 1.04%, however, over the last 30 days, the volatility rate increased by 1.30%, as shares surge +7.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.33% upper at present.
During the last 5 trading sessions, SNY fell by -1.44%, which changed the moving average for the period of 200-days by +24.17% in comparison to the 20-day moving average, which settled at $56.26. In addition, Sanofi ADR saw 15.86% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.66 for the gross margin
The net margin for Sanofi ADR stands at 0.12. The total capital return value is set at 0.15. Equity return is now at value 5.80, with 3.31 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at 0.37. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is 10.13.
Currently, EBITDA for the company is 12.96 billion with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 2.19. The receivables turnover for the company is 7.71for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.00.
Conclusion
In conclusion, Sanofi ADR (SNY) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
